An interventional study of Variable Compression System in IBS (Irritable Bowel Syndrome), sponsored by PGP Health. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by PGP Health · Not applicable, Interventional, and Treatment
This prospective, interventional trial is intended to determine the safety and effectiveness of the Variable Compression System (VCS) device for Irritable Bowel Syndrome (IBS). This pilot study will enroll 20 subjects who will be required to wear the VCS device for a minimum of 6 hours a day and follow up at 21 days, 8 weeks, and 6 months post-device administration.
1,062 studies on the registry are indexed under Irritable Bowel Syndrome; 190 are open to participants now.
This study's planned enrollment of 20 is below the median of 71 across 853 interventional studies indexed under Irritable Bowel Syndrome.
Browse Irritable Bowel Syndrome studies →This is the only study on the registry with PGP Health as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Wear VCS device for 6+ hours per day
Device: Variable Compression System
The VCS is a wearable device that provides compression of the lower abdomen, torso support, and covers the torso in Far Infrared Radiation (FIR).
Incidence of intolerable treatment-related adverse events (AEs)
Time frame: 21 days
Incidence, severity, and causal relationship of treatment-emergent AEs (TEAEs)
Time frame: 21 days
Change in IBS-related symptoms
Time frame: 21 days
Long-term impact of VCS use
To assess the long-term change in IBS symptoms after utilizing VCS.
Time frame: 8 weeks, 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.